Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.

ABSTRACT:

SUBMITTER: Heaney LG 

PROVIDER: S-EPMC7783382 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature